Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
1. A method of decreasing seizures in a subject with a high 4R:3R tau isoform ratio, the method comprising administering an antisense oligonucleotide to the subject, wherein the method decreases the 4R:3R tau ratio in the central nervous system of the subject, wherein the antisense oligonucleotide comprises a nucleobase sequence of SEQ ID NO:12, wherein the antisense oligonucleotide comprises a non-bicyclic 2′-modified sugar moiety, and wherein the substituent at the 2′-position is 2′-O-methoxyethyl (MOE); wherein the subject has frontotemporal dementia.
2. The method of claim 1 , wherein the high 4R:3R tau isoform ratio in the subject is caused by a splicing defect.
3. The method of claim 1 , further comprising decreasing the accumulation of aggregated tau in the brain and spinal cord of the subject.
4. The method of claim 1 , wherein the oligonucleotide is administered using a single bolus administration.
5. The method of claim 1 , wherein the oligonucleotide is administered using a pump.
6. The method of claim 1 , wherein the total amount of tau in the central nervous system is not changed.
7. A method of modifying a neurodegenerative syndrome in a subject with a high 4R:3R tau isoform ratio, the method comprising administering an antisense oligonucleotide to the central nervous system of the subject, wherein the antisense oligonucleotide decreases the high 4R:3R tau ratio in the central nervous system of the subject, wherein the antisense oligonucleotide has a nucleobase sequence of SEQ ID NO:12, wherein the antisense oligonucleotide comprises a non-bicyclic 2′-modified sugar moiety, and wherein the substituent at the 2′-position is 2′O-methoxyethyl (MOE); wherein the neurodegenerative syndrome in the subject is frontotemporal dementia.
8. The method of claim 7 , wherein the high 4R:3R tau isoform ratio in the subject is caused by a splicing defect.
9. The method of claim 7 , wherein the neurodegenerative syndrome is a neurodegenerative syndrome associated with tau.
10. The method of claim 9 , wherein the neurodegenerative syndrome associated with tau is associated with tau multimerization.
11. The method of claim 7 , wherein modifying a neurodegenerative syndrome improves the behavioral phenotype of the subject.
12. The method of claim 11 , wherein the behavioral phenotype of the subject is seizures.
13. The method of claim 7 , wherein modifying a neurodegenerative syndrome slows the progression of neurodegenerative disease development in the subject.
14. The method of claim 7 , wherein modifying a neurodegenerative syndrome decreases the accumulation of aggregated tau in the brain and spinal cord of the subject.
15. The method of claim 7 , wherein the oligonucleotide is administered using a single bolus administration.
16. The method of claim 7 , wherein the oligonucleotide is administered using a pump.
17. The method of claim 7 , wherein the abnormal 4R:3R tau ratio in the central nervous system is decreased without decreasing the total amount of tau in the central nervous system.